TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search
PRESS RELEASES

BiondVax Announces Topline Results From Phase 3 Clinical Trial Of The M-001 Universal Influenza Vaccine Candidate

PRESS RELEASES

BiondVax Announces At-The-Market (ATM) Equity Offering Program

PRESS RELEASES

BiondVax Announces Notice Of Annual General Meeting Of Shareholders And Provides A Clinical Trial Update

PRESS RELEASES

NIH Report On Phase 2 Clinical Trial Of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved

PRESS RELEASES

BiondVax Announces Receipt Of $4.2 Million Through Exercise Of Warrants

PRESS RELEASES

BiondVax Announces Upcoming Expiration Of Public Warrants

PRESS RELEASES

New Directors Elected To BiondVax's Board Of Directors

PRESS RELEASES

BiondVax's CEO Comments On Impact Of COVID-19 Pandemic On The Company's Ongoing Phase 3 Clinical Trial

PRESS RELEASES

Preliminary Data From NIH/NIAID-sponsored Phase 2 Clinical Trial Of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results Of Previous Clinical Trials

PRESS RELEASES

BiondVax Announces Warrant Agreement Amendment To Permit Holders Of Warrants To Exercise Both On A Cash And Cashless Basis